LOW-DOSE OCTREOTIDE IS ABLE TO CAUSE A MAXIMAL INHIBITION OF THE GLYCEMIC RESPONSES TO A MIXED MEAL IN OBESE TYPE-2 DIABETIC-PATIENTS TREATED WITH INSULIN

Short-term studies have shown that octreotide, a long-acting somatostatin analog, blunts postprandial glycemic responses and reduces insulin requirement in insulin treated diabetic patients. The aim of our study was to investigate the effects of three single, different doses of octreotide on the glycemic response to a mixed meal in eight insulin treated type 2 diabetic patients after secondary failure with hypoglycemic agents. Previous treatments were substituted by regular insulin, 0.5 U/kg/day divided into three sc injections, for at least seven days. All patients received: (a) regular insulin (0.1 U/kg, sc) at 7.30 am; (b) octreotide 25-mu-g sc or (c) 50-mu-g sc or (d) 100-mu-g sc simultaneously with insulin but injected at different sites. From 8.00 to 8.15 the patients consumed a preconstituted fluid mixed meal of 250 ml. Following insulin alone a significant increase in blood glucose levels was observed after the meal. Abolished and not significantly different blood glucose responses to the meal after each of the three doses of octreotide were observed. Our findings suggest that with a low dose of octreotide (25-mu-g) it is possible to abolish the postprandial glycemic peak in type 2 diabetic patients treated with insulin.